Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: The phase 3 KEYNOTE-181 study

Takashi Kojima, et al.

First-line pembrolizumab, trastuzumab, capecitabine and oxaliplatin in HER2-positive metastatic esophagogastric adenocarcinoma

Yelena Y. Janjigian, et al.

Efficacy and safety of dabrafenib + trametinib in patients with BRAF V600E-mutated biliary tract cancer: A cohort of the ROAR basket trial

Zev A. Wainberg, et al.

Integrative genomic and transcriptomic profiling and response to chemotherapy on the COMPASS trial

Grainne M. O’Kane, et al.

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05)

Michiaki Unno, et al.

A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results

Carl Christoph Schimanski, et al.

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Big Ten Cancer Research Consortium Study BTCRC-ESO14-012

Hirva Mamdani, et al.

Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502)

Ken Kato, et al.

A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: the ACTS-CC 02 trial

Takao Takahashi, et al.